Quick answer
What does ≥98% purity mean for CJC-1295? It is a chromatographic statement: by reverse-phase HPLC, the main peak accounts for at least 98% of the integrated peak area at the detection wavelength. It does not state the fraction of the powder that is peptide (the rest being counter-ion and water), does not prove identity, and cannot see impurities that co-elute or do not absorb. The product page lists ≥98% HPLC purity for the no-DAC peptide, with identity reported on the certificate of analysis where published. For laboratory research use only.
A purity number is the first thing a researcher reads and the thing least often interrogated. This article explains what the figure measures for a 29-residue modified GHRH analog, what kinds of impurity a peptide of this type can carry, and what further information a quantitative assay needs. It complements CJC-1295 No DAC purity testing, which covers the testing workflow, by focusing on interpretation. For laboratory research use only; not for human consumption.
Where impurities come from
The peptide is made by solid-phase synthesis: amino acids are coupled one at a time onto a resin-bound chain, a method introduced by Merrifield (1963). After cleavage and deprotection the crude product is purified, usually by preparative reverse-phase HPLC, and then lyophilized. A 29-mer needs 28 coupling cycles, and even at high efficiency per step the cumulative yield of the full-length product is well below 100%, which is why purification is needed. The categories of related impurity in peptide medicines are cataloged by D’Hondt and colleagues (2014), and they apply equally to research peptides.
| Impurity class | Origin | Relevance to a 29-mer such as CJC-1295 |
|---|---|---|
| Deletion sequences | Incomplete coupling at one residue | Peptide missing one residue; often elutes close to the main peak |
| Truncations | Chain termination | Shorter peptides, usually well separated |
| Insertion sequences | Double coupling | Peptide with an extra residue |
| Incomplete deprotection | Side-chain protecting group remains | Relevant for arginine, tyrosine, aspartate and other protected residues |
| Racemization | Base- or activation-induced epimerization | Matters for the D-Ala at position 2, where the stereochemistry is the design |
| Deamidation / isomerization | Storage or processing in solution | Slow change at glutamine and aspartate positions (aspartyl chemistry: Geiger and Clarke, 1987) |
| Oxidation | Air, light, impurities | Tyrosine, mainly |
What the purity percentage measures
In reverse-phase HPLC the sample is loaded onto a hydrophobic column and eluted with an increasing proportion of organic solvent while the detector (often ultraviolet absorbance near 214 nm for peptide bonds) records signal against time. Purity by area percent is main peak area ÷ total peak area × 100. The figure depends on method choices: gradient steepness, column chemistry, wavelength and integration rules all change which impurities separate and how large they appear. Two laboratories analyzing one sample can report different percentages without either being wrong. The principles are described in understanding HPLC purity.
What the number does not capture is the list below.
- Co-eluting impurities. A deletion sequence with nearly the same hydrophobicity may sit under the main peak.
- Non-absorbing material. Salts, counter-ions and water are invisible at 214 nm.
- Peptide content. A lyophilized peptide is not 100% peptide by weight. It carries counter-ion from purification and residual water. A label mass of 5 mg therefore refers to the nominal powder, and the true peptide mass can be lower.
- Identity. A single clean peak tells you the sample is one thing, not that it is the right thing. Identity is confirmed by mass or sequence analysis; see HPLC versus mass spectrometry.
- Biological activity. Chromatographic purity does not guarantee receptor activity; a stereochemical or conformational change can keep the peak and lose function.
Counter-ions: a variable that matters in cell work
Reverse-phase purification commonly uses trifluoroacetic acid, so the peptide is typically isolated as a trifluoroacetate salt. Cornish and colleagues (1999) reported that trifluoroacetate, as a contaminant in purified proteins, inhibited proliferation of osteoblasts and chondrocytes in culture. The point for a laboratory is limited and practical: in a proliferation or viability assay, a salt form can contribute to the readout, and a vehicle control that matches the salt is wise. For short-term receptor-signaling assays the effect is less likely to matter, but the possibility should be stated, not assumed away. Which counter-ion a lot carries is not something this article can state; where a certificate lists it, use it.
Checks for identity and content
| Question | Method | What it adds |
|---|---|---|
| Is the main peak the right molecule? | Mass spectrometry; sequence analysis | Observed mass compared with the expected mass from the formula (C152H252N44O42, about 3,368 g/mol on the product page) |
| How much of the powder is peptide? | Amino acid analysis; nitrogen content; quantitative NMR | True peptide mass for molar calculations |
| Are there hidden impurities? | Orthogonal HPLC (different column or pH) | Separates peaks that co-elute in the first method |
| How much water is present? | Karl Fischer titration | Residual moisture in the cake |
| Has the stock changed over time? | Repeat HPLC against day zero | Stability data for the prepared solution (Hawe and colleagues, 2012) |
Most routine bench work does not need all of these. The decision rule is whether the experiment’s conclusion depends on an absolute concentration or only on comparison between arms prepared the same way. Comparative work tolerates peptide-content uncertainty; potency measurement does not.
Reading the product page and certificate
The product page lists ≥98% purity by HPLC, with sequence or identity confirmation reported on the certificate of analysis where published. Read certificate fields as separate pieces of information: the purity figure, the analytical method, the lot number and the test date. A certificate without a lot number cannot be tied to a vial. How to read a COA walks through each field, and third-party testing explained covers independent verification. Published certificates are in the COA library; if none is listed for a lot, record that.
When purity numbers should change what you do
- Molar potency experiments. Use a measured peptide content, or state that nominal mass was used and the resulting concentration is an upper bound.
- Proliferation or viability assays. Add a counter-ion-matched vehicle control.
- Long studies. Re-run HPLC on stored stock at intervals and keep the chromatograms.
- Comparisons between lots. Compare chromatograms under the same method, not percentages from different laboratories.
- Anything surprising. Check identity first; many apparent biological anomalies are material anomalies.
Preparation steps are in how to reconstitute a lyophilized peptide; concentration arithmetic is in the calculator. Background on the compound is in the CJC-1295 No DAC overview.
Frequently asked questions
What does 98% purity mean on a peptide?
It means the main peak is at least 98% of the integrated area in an HPLC chromatogram under the stated method. It does not mean 98% of the powder by weight is peptide.
Does HPLC purity confirm the peptide is CJC-1295?
No. It shows that one species dominates, not which species. Identity needs mass or sequence confirmation, reported on the certificate where published.
What impurities can a 29-residue peptide contain?
Deletion and truncation sequences, insertion sequences, incompletely deprotected material, racemized residues, and degradation products such as deamidated or oxidized forms.
Why can two HPLC reports of the same sample differ?
Gradient, column, wavelength and integration rules change which impurities separate and how they are counted, so percentages from different methods are not directly comparable.
What is peptide content?
The fraction of the powder that is peptide by weight. The remainder is counter-ion and water. It matters when exact molar concentration is needed.
Why does trifluoroacetate matter?
It is a common residue of purification. In one report it inhibited proliferation of osteoblasts and chondrocytes in culture, so proliferation assays may need a counter-ion-matched vehicle control.
How do I check identity myself?
Compare the observed mass from mass spectrometry with the expected mass calculated from the formula, which is about 3,368 g/mol for CJC-1295 (no DAC).
Do I need orthogonal HPLC?
Only when conclusions depend on hidden co-eluting impurities not being present; a second method with a different column or pH separates peaks that overlap in the first.
Where is the certificate for my vial?
In the COA library where a certificate is published for the lot. If none is listed, record that in your notebook.
Does purity change after reconstitution?
It can, through slow chemical change and adsorption. Repeat HPLC against day zero when the stock is used over weeks.
Related reading: How to Reconstitute CJC-1295 No DAC: Bench Workflow, CJC-1295 Research Reference Sheet: Terms and Numbers.
References
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. J Biol Chem. 1987;262(2):785-794. doi:10.1016/S0021-9258(19)75855-4
- Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. doi:10.1152/ajpendo.1999.277.5.E779
- Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
